The biotechnology sector is a high-stakes arena where scientific innovation meets financial strategy. For companies navigating this landscape, the decision to go public or seek acquisition is pivotal.
Each path – whether through an Initial Public Offering (IPO), a merger with a Special Purpose Acquisition Company (SPAC), or a traditional Mergers and Acquisitions (M&A) deal – carries distinct advantages, risks, and operational demands. This primer delves into the mechanics of these strategies, supported by real-world examples, market trends, and strategic insights to guide biotechs in their growth journeys.
Initial Public Offerings (IPOs): The Traditional Gateway to Public Markets
An IPO represents the conventional route for biotechs aiming to access public capital markets. This process involves transitioning from private to public ownership by listing shares on exchanges like the NASDAQ or NYSE. For biotech firms, IPOs are often pursued to secure funding for late-stage clinical trials, scale manufacturing, or expand commercialization efforts.
The IPO journey begins with rigorous preparation.
Companies collaborate with investment banks, legal teams, and auditors to compile financial disclosures and draft the Form S-1 registration statement, a document scrutinized by the Securities and Exchange Commission (SEC). The S-1 details the company’s business model, risk factors, financial health, and leadership, ensuring transparency for potential investors. Following SEC approval, executives embark on a roadshow to pitch the company’s value proposition to institutional investors. Pricing is determined based on investor demand, with shares debuting on the exchange shortly thereafter.
In 2023, RayzeBio’s IPO exemplified this process. The radiopharmaceutical firm priced its shares at $18, raising $358 million to advance its pipeline. However, market volatility often impacts post-IPO performance. Abivax, a clinical-stage biotech focused on inflammatory diseases, saw its shares drop from $11.60 to $10.16 within a month of its 2023 Nasdaq debut, reflecting investor caution toward pre-revenue companies.
Advantages and Challenges
IPOs offer access to substantial capital pools – often $50–500 million – while enhancing corporate credibility and providing liquidity for early investors. However, the process is costly, with fees ranging from $5–15 million, and exposes companies to market fluctuations. Regulatory scrutiny is intense, requiring meticulous compliance with SEC reporting standards.
Moreover, biotechs face pressure to deliver clinical milestones post-IPO, as seen in the 2024 downturn, where only 16 of 19 biotech IPOs involved firms with clinical-stage assets.
SPACs: Speed and Flexibility in Going Public
SPACs, or “blank-check companies,” emerged as a popular alternative to traditional IPOs during the 2020s. These shell companies raise capital through their own IPOs with the sole purpose of acquiring a private firm, thereby taking it public. For biotechs, SPAC mergers offer accelerated timelines and valuation certainty, though they come with unique risks.
The SPAC lifecycle starts with sponsors forming a shell company and raising funds through an IPO, typically priced at $10 per share. These funds are held in trust while the SPAC identifies a target – often within 18–24 months. Upon selecting a biotech, shareholders vote on the merger (a “de-SPAC” transaction). Dissenting investors can redeem their shares for cash, a feature that has led to high redemption rates in volatile markets. Post-merger, the combined entity lists on an exchange, with the biotech gaining access to the SPAC’s capital.
Ginkgo Bioworks’ 2021 SPAC merger with Soaring Eagle Acquisition Corp illustrates both the potential and pitfalls of this route. Valued at $17.5 billion, Ginkgo’s synthetic biology platform attracted significant hype. However, its stock plummeted 65% within a year, highlighting the risks of speculative valuations. Similarly, Cerevel Therapeutics’ 2020 merger with Arya Sciences Acquisition Corp III secured $445 million but faced post-merger volatility due to investor skepticism about its neuroscience pipeline.
Strategic Considerations
SPACs appeal to biotechs seeking rapid liquidity – deals often close in 3–6 months, compared to 6–12 months for IPOs. They also bypass some regulatory hurdles, as the target company’s financials are disclosed in a proxy statement rather than an S-1.
However, challenges abound. Shareholder redemptions can drain trust funds, leaving the biotech with less capital than anticipated. Additionally, Private Investment in Public Equity (PIPE) financing, often used to supplement SPAC funds, dilutes existing shareholders. The SEC’s 2024 tightening of SPAC regulations, including stricter liability for forward-looking statements, has further tempered enthusiasm
Mergers and Acquisitions: Strategic Exits for Growth
M&A activity remains a cornerstone of biotech growth strategies, enabling firms to leverage the resources of larger pharmaceutical companies. Acquisitions are driven by pharma’s need to replenish pipelines, address patent expirations, or enter new therapeutic areas. For biotechs, M&A offers immediate liquidity and access to global distribution networks, albeit at the cost of independence.
The M&A process begins with target identification, followed by due diligence, valuation, and negotiation. Deals often hinge on clinical data, intellectual property, and strategic fit. In 2021, AstraZeneca’s $39 billion acquisition of Alexion Pharmaceuticals underscored the value of rare disease portfolios, adding blockbuster drugs like Soliris to its arsenal. Similarly, Gilead’s $21 billion purchase of Immunomedics in 2020 secured Trodelvy, an antibody-drug conjugate for metastatic breast cancer, bolstering its oncology division.
Amgen’s 2023 acquisition of Horizon Therapeutics marked a strategic pivot into rare diseases. Horizon’s Tepezza, a therapy for thyroid eye disease, complemented Amgen’s inflammation portfolio while diversifying revenue streams amid biosimilar competition. The deal faced antitrust scrutiny but ultimately demonstrated how M&A can mitigate pipeline risks for large pharma.
Pros and Cons
M&A provides biotechs with immediate capital and infrastructure, reducing the burden of clinical development. However, integration challenges – such as aligning corporate cultures and managing layoffs – can erode value. For acquirers, overpaying for assets remains a risk, as seen in Bristol Myers Squibb’s 2019 $74 billion acquisition of Celgene, which struggled with pipeline setbacks.
Comparative Analysis: IPO vs. SPAC vs. M&A
Choosing between these pathways requires a nuanced understanding of timelines, costs, and strategic goals.
- Timelines: IPOs typically take 6–12 months, while SPACs offer a faster 3–6 month window. M&A timelines vary but often conclude within 3–9 months, depending on regulatory approvals.
- Costs: IPOs incur $5–15 million in fees, SPACs $10–20 million (including PIPE financing), and M&A $1–5 million in advisory fees.
- Control: Founders retain control post-IPO but face shareholder pressure. SPACs dilute ownership through PIPE investments, while M&A transfers control to the acquirer.
- Capital Raised: IPOs and SPACs provide $50–500 million and $100 million–$1 billion, respectively. M&A delivers the full acquisition price upfront, often exceeding $1 billion for late-stage assets.
Market Trends Shaping 2026 and Beyond
- IPO Market Recovery:
After a 60% decline in biotech IPOs from 2021–2023, 2024–2025 has seen a resurgence, driven by advancements in AI-driven drug discovery and gene editing. Analysts project 50+ listings in 2025, with firms like CAR-T leader Caribou Biosciences eyeing public debuts. - SPAC Evolution:
Serial SPAC sponsors dominate the market, accounting for 80% of Q1 2025’s $3.1 billion raises. However, stricter SEC rules on sponsor compensation and investor disclosures have curtailed speculative deals, favoring targets with Phase II+ assets. - M&A Resurgence:
Pharma giants, sitting on $1.3 trillion in acquisition “firepower,” are targeting neurology, oncology, and metabolic disease innovators. Pfizer’s $43 billion takeover of Seagen in 2023 exemplifies this trend, expanding its ADC (antibody-drug conjugate) capabilities. - Biosimilar Pressures:
With 118 biologics losing patent protection by 2034, biosimilar competition is expected to save $234 billion in healthcare costs. Originator firms are countering through acquisitions, as seen in Novo Nordisk’s 2024 purchase of a gene therapy startup to diversify beyond diabetes.
Strategic Recommendations for Biotechs
- Late-Stage Firms: Pursue IPOs to fund Phase III trials, leveraging strong clinical data to attract institutional investors.
- Pre-Revenue Innovators: Consider SPACs for rapid capital access but prepare for post-merger volatility and dilution.
- Niche Therapies: Opt for M&A to align with pharma partners capable of scaling distribution and navigating regulatory pathways.
Conclusion: Navigating the Crossroads
The biotech sector’s dynamic landscape demands agility and strategic foresight.
While IPOs offer traditional credibility, SPACs provide speed, and M&A delivers immediate scale, each path requires careful alignment with a company’s stage, assets, and market conditions. As regulatory frameworks evolve and technological breakthroughs accelerate, biotechs must remain adaptable, balancing innovation with financial pragmatism to thrive in an increasingly competitive arena.